Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Eltrombopag (Promacta), a platelet-enhancing drug indicated for the treatment of thrombocytopenia, has been shown to increase erythrocyte production in patients with aplastic anemia who were non-responders to immunosuppressants
Furthermore, the 5 mg, 10 mg, and 15 mg doses exhibited superior weight loss and glycemic control relative to dulaglutide (1.5 mg), while maintaining an acceptable safety and tolerability profile
Karger, 189-201, 2000
These symptoms are typically more common with higher-strength preparations
Similarly, there are reports of patients with psoriasis and metabolic syndrome being treated with GLP-1 receptor agonists in clinical practice, with some suggesting potential improvements in inflammatory markers, though causality cannot be established from these observations
